ResMed share price on watch after Q3 revenue and earnings miss

ResMed had a softer than expected quarter…

| More on:
young female doctor with digital tablet looking confused.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ResMed shares will be on watch after the release of its third quarter update
  • The company's results appear to have fallen short of the market's estimates for revenue and earnings
  • Margin pressures weighed heavily on ResMed's earnings

The ResMed Inc (ASX: RMD) share price will be one to watch on Friday.

This follows the release of the sleep treatment focused medical device company’s third quarter update.

ResMed share price on watch after earnings miss

  • Revenue up 12% (14% in constant currency) to US$864.5 million
  • Gross margin down 150 basis points to 58.1%
  • Operating income up 5% to US$234.3 million
  • Earnings per share up 2% to US$1.32

What happened during the quarter?

For the three months ended 31 March, ResMed reported a 12% increase in revenue to US$864.5 million and a 2% lift in earnings per share to US$1.32. This fell short of consensus estimates by US$35.5 million and 12 US cents, respectively.

According to the release, ResMed’s top line growth was driven by increased demand for its sleep and respiratory care devices and increased demand in response to a recent product recall by one of its competitors.

Revenue in the U.S., Canada, and Latin America, excluding software-as-a-service, grew by 18% during the quarter. It was a similar story overseas, with the company reporting an 11% increase in revenue in Europe, Asia, and other markets.

ResMed’s software-as-a-service revenue increased by 8% during the three months. This was due to continued growth in its Durable Medical Equipment category and stabilising patient flow in out-of-hospital care settings.

However, offsetting much of this top line growth was a 150 basis point contraction in ResMed’s gross margin. This was mainly due to higher freight and manufacturing costs, which were partially offset by favourable product mix changes and increase in average selling prices.

In addition, the company’s operating expenses grew quicker than revenue during the period. This was mainly due to higher employee-related expenses. This ultimately led to operating income rising just 5% and earnings per share increasing a modest 2% for the period.

Management commentary

ResMed’s CEO, Mick Farrell, commented:

“Our third-quarter results reflect strong performance across our business, resulting in double-digit top-line revenue growth including extraordinary demand in our sleep and respiratory care business segment as well as solid high-single-digit growth in our software-as-a-service segment.

“I am proud of our global team’s ability to pivot and drive continued growth while ongoing supply chain disruptions and a competitor’s recall continue to limit our ability to meet the incredible demand for our products. We remain focused on delivering products, software, and services for patients, working closely with our supply chain partners as well as physicians, providers, and beyond, to prioritize care for patients who most need it.

“While the current industry and macroeconomic environment remain uncertain, our long-term strategy allows us to keep our focus on helping 250 million lives in 2025. Our end-market demand from patients and providers remains strong, and our digital health technologies continue to deliver value. We are supporting patients with the world-leading portfolio of sleep apnea therapy, respiratory care therapy, and digital health solutions they need, as we deliver value for all of our customers.”

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two researchers discussing results of a study with each other.
Healthcare Shares

Here’s how ASX 200 healthcare shares performed in June

Healthcare shares were a tad ill in June.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

What’s the outlook for the CSL share price in July?

We take a look at what the experts are saying about the biotech company's shares.

Read more »

Photo of a group of scientists cheering while working in a lab as the Race Oncology share price skyrockets today on positive study results
Healthcare Shares

Why is the Race Oncology share price soaring 13% today?

New trial results have excited ASX investors.

Read more »

Rising arrow on a blue graph symbolising a rising share price.
Healthcare Shares

Starphama share price lunges 5% on product relaunch

Early support for Starphama on Thursday has it off to a great start.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Why is the Paradigm share price rocketing 20% higher today?

The Paradigm share price is having a very strong day...

Read more »

A businessman presents a company annual report in front of a group seated at a table
Healthcare Shares

Own Immutep shares? Here are 3 takeaways from the company’s investor update

Investors were mute to the update.

Read more »

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
Healthcare Shares

Has CSL been growing its dividend?

Is the biotech giant still increasing its dividends in a post-COVID world?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why is the 4DMedical share price exploding 40% today?

4DMedical signed a three-year, nationwide contract with I-MED Radiology Network.

Read more »